Bispecific antibodies enable synthetic agonistic receptor T-cell therapy in melanoma
Florian Märkl • 3 Oct 2022
Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Keep up to date with all the latest news with our monthly newsletter